Skip to main content

Table 2 Factors related to SF36-MCS and PCS over 5 to 8 years in early arthritis (EA) and early inflammatory back pain (IBP): results of univariate mixed linear models

From: Similar alteration for mental and physical aspects in health-related quality of life over 5 to 8 years in 1347 patients with early arthritis and early inflammatory back pain

Characteristics associated to HRQoL EA Early IBP
MCS beta (p value) PCS beta (p value) MCS beta (p value) PCS beta (p value)
Baseline characteristics
 Age − 0.0049 (0.055) − 0.0086 (0.001) − 0.00031 (0.69) − 0.0017 (0.003)
 Gender − 0.0056 (0.93) + 0.041 (0.50) + 0.00075 (0.96) + 0.016 (0.12)
 Level of studies − 0.029 (0.66) + 0.20 (0.003) − 0.013 (0.33) + 0.017 (0.11)
 Level employment + 0.017(0.82) + 0.12 (0.04) + 0.026 (0.06) − 0.010 (0.32)
 Baseline MCS-SF36 − 0.041 (< 0.001) + 0.0012 (0.007) − 0.0083 (< 0.001) + 0.0013 (0.004)
 Baseline PCS-SF36 − 0.0048 (0.19) − 0.038 (< 0.001) − 0.00001 (0.99) − 0.0052 (< 0.0001)
 Smoking status − 0.097 (0.11) − 0.049 (0.33) + 0.0058 (0.68) + 0.0077 (0.46)
 HLAB27 status NA NA + 0.011 (0.42) − 0.0062 (0.54)
 Radiological or MRI sacroiliitis NA NA − 0.012 (0.39) + 0.016 (0.12)
 Symptom duration + 0.0012 (0.04) + 0.0025 (< 0.001) + 0.0062 (0.42) − 0.015 (0.008)
Variables changing over time
 Erosions on hands and/or feet + 0.54 (0.19) + 0.32 (0.36) NA NA
 Oral corticosteroid + 0.13 (0.10) + 0.20 (0.002) NA NA
 DMARDs + 0.36 (< 0.001) + 0.61 (< 0.001) NA NA
 DAS28-ESR/ASDAS-CRP + 0.20 (< 0.001) + 0.27 (< 0.001) + 0.0062 (0.39) − 0.016 (0.0005)
 Extra articular manifestations NA NA − 0.0037 (0.80) + 0.00001 (1.00)
 Peripheral arthritis NA NA + 0.029 (0.04) + 0.018 (0.09)
 Enthesitis NA NA + 0.014 (0.36) + 0.015 (0.19)
 TNFi NA NA − 0.021 (0.21) − 0.027 (0.03)
  1. DAS28-CRP was applied to EA and ASDAS-CRP to early IBP
  2. MCS mental composite score, PCS physical composite score, ASDAS-CRP Ankylosing Spondylitis Disease Activity Score—C reactive protein, DAS28-ESR Disease Activity Score 28—erythrocyte sedimentation rate, TNFi tumor necrosis factor inhibitor, NA not analysed
  3. †Extra-articular manifestations including uveitis, psoriasis or inflammatory bowel disease